Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VENT 01

Next Previous
X
Search
Drug Profile

VENT 01

Alternative Names: NLRP3 inhibitor - Ventus Therapeutics; VENT-01

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ventus Therapeutics
  • Class Anti-inflammatories; Cardiovascular therapies; Hepatoprotectants; Small molecules; Urologics
  • Mechanism of Action NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Preclinical Cardiovascular disorders; Kidney disorders; Liver disorders; Neurological disorders
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 03 May 2024 Ventus Therapeutics initiates enrolment in a phase I trial for Healthy volunteers (PO)
  • 24 Aug 2023 9396858: No update
  • 13 Oct 2022 Preclinical trials in Cardiovascular disorders in USA (PO) (Ventus Therapeutics pipeline, October 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top